Sign in
Taking people in United StatesNo phase

Registry following pregnancies in women taking solriamfetol for narcolepsy or sleep apnea

Follows pregnant women with narcolepsy or obstructive sleep apnea and their babies, studying solriamfetol exposure.

Key facts

Who runs it
Axsome Therapeutics, Inc.
Where
Morrisville and Wilmington, United StatesSee the 2 sites
Trial code
Registry title
SUNOSI® (Solriamfetol) Pregnancy Registry
Status
Recruiting
People taking part
1,731 people, planned
Started
31 Jul 2019
Expected to end
Sept 2029
Type of study
Observational, 5 groups
Treatments tested
  • Sunosi (solriamfetol)
  • Other prescription wake-promoting medications or stimulants
  • No treatment
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women in the US or Canada who have narcolepsy or obstructive sleep apnea, or who took solriamfetol or other wake-promoting medicines or stimulants. It only observes and collects safety data.

Age
Any age
Sex
Women only
Disease stage
Narcolepsy or obstructive sleep apnea (OSA) diagnosis, or use of solriamfetol or other wake-promoting medicines or stimulants. Some groups have no narcolepsy or OSA.
Earlier treatment
Groups are formed by use of solriamfetol or other wake-promoting medicines or stimulants during pregnancy or in the relevant time before conception, or no such treatment.

Main reasons for not taking part

  • The pregnancy outcome happened before the first contact with the registry coordination center
  • Not living in the US or Canada
  • Not giving written consent
  • Not allowing her healthcare providers to share data with the registry

This trial only enrols pregnant participants. The registry sentence this rests on: * Pregnant women of any age

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Pregnant women of any age
  • Diagnosed with narcolepsy or obstructive sleep apnea OR has taken solriamfetol or other wake promoting medications or stimulants during pregnancy or in the relevant exposure window before conception
  • Resident of the US or Canada
  • Provides written informed consent to participate in the study
  • Authorization for her HCP(s) to provide data to the registry

Who cannot take part

  • Occurrence of pregnancy outcome prior to first contact with the registry coordination center (RCC)

Where in United States

  • Evidera, a PPD business unitMorrisville, United StatesContact: Study DirectorTaking people
  • PPD, Inc.Wilmington, United StatesContact: Study DirectorTaking people

About the trial

What the trial wants to find out

The SUNOSI (solriamfetol) Pregnancy Registry is a US- and Canada-based prospective, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).

The 5 groups in the trial

  • Cohort 1: Solriamfetol-exposed participants with narcolepsy or OSA

    Pregnant women with a diagnosis of narcolepsy or OSA

    Treatment: Sunosi (solriamfetol)

  • Cohort 2: Unexposed participants with narcolepsy or OSA

    Pregnant women with a diagnosis of narcolepsy or OSA

    Treatment: No treatment

  • Cohort 3: Other-exposed participants with narcolepsy or OSA

    Pregnant women with a diagnosis of narcolepsy or OSA

    Treatment: Other prescription wake-promoting medications or stimulants

  • Cohort 4: Solriamfetol-exposed participants without narcolepsy or OSA

    Pregnant women without a diagnosis of narcolepsy or OSA

    Treatment: Sunosi (solriamfetol)

  • Cohort 5: Other-exposed participants without narcolepsy or OSA

    Pregnant women without a diagnosis of narcolepsy or OSA

    Treatment: Other prescription wake-promoting medications or stimulants

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SUNOSI® (Solriamfetol) Pregnancy Registry: An Observational Study on the Safety of Solriamfetol Exposure in Pregnant Women and Their Offspring
Plain-language title
Registry following pregnancies in women taking solriamfetol for narcolepsy or sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
5 October 2026